IPO

● Odyssey Therapeutics reported $433.1 million in cash as of June 30, 2026, funding operations into the second half of 2028, with fuller induction data for RIPK2 inhibitor OD-001 due at United European Gastroenterology Week in October 2026.

● Generate Biomedicines priced its IPO at $16.00 per share on February 26, 2026 but closed its debut session around $12.65, roughly 21% below offer, while reporting a 2025 net loss of about $223 million.

● Kardigan listed on June 18, 2026 at $16.00 per share, raising roughly $400 million, and traded near $18.50 with a marketCapitalizationaround $1.73 billion by mid-September 2026.

● Bending Spoons priced its IPO at $29 per share and began trading onNasdaqon July 1, 2026, raising roughly $1.68 billion, then agreed on September 10, 2026 to acquire Miro for about $1.355 billion in cash.

● Hemab Therapeutics priced an upsized IPO at $18 per share on April 30, 2026, raising about $346.7 million in total proceeds, and its stock jumped almost 89% on debut.

● Eloxx Pharmaceuticals priced a $66.0 million public offering and uplisted toNasdaqin June 2026, advancing exaluren through the Phase 2b EXACT Study in Alport syndrome with topline data expected mid-2027.

Founded in 1986 by Dr. Krishna P. Singh, who remains Chairman and CEO, Holtec built itsBusinesson unglamorous but highly defensible ground: spent nuclear fuel storage. Today it holds roughly 90% U.S.Market Sharein wet fuel storage and about 75% share in dry storage — moats …